Qyuns Therapeutics Raises Profit-Sharing Caps for Psoriasis Drug Through 2028

MT Newswires Live10-27

Qyuns Therapeutics (HKG:2509) proposed raising annual profit-sharing caps for its psoriasis drug QX001S to 120 million yuan in 2026, 210 million yuan in 2027 and 310 million yuan in 2028.

QX001S is a biosimilar of ustekinumab, marketed as SAILEXIN and SAIJIENING in China. The company said the revised caps reflect rising demand for the drug, according to a Wednesday Hong Kong bourse filing.

Qyuns also proposed raising annual caps for drug supplies to its commercialization partner, Hangzhou Zhongmei Huadong Pharmaceutical, to 25 million yuan in 2026, 42 million yuan in 2027 and 57 million yuan in 2028. Both proposals require independent shareholder approval at a Nov. 13 meeting.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment